Zensar Technologies to buy US firm BridgeView Life Sciences

Zensar Technologies, has agreed to acquire a 100% membership interest in three-year old US-based BridgeView Life Sciences, through its wholly owned subsidiary Zensar Technologies Inc, USA, for a total consideration of $25 million.

Under the terms, Zensar said will make an aggregate upfront payment of $14.0 million subject to customary adjustments for working capital, debt and cash on closing and additional payment upto $11.0 million by 31 December, 2027 contingent on achievement of performance and employment continuity thresholds.